Kape Technologies & ExpressVPN Announce Zac Eller as GM, Global Partnerships & Business Development
14.8.2024 15:00:00 EEST | Business Wire | Press release
Kape Technologies and ExpressVPN today announce the appointment of Zac Eller as GM, Global Partnerships & Business Development, strengthening the group’s senior commercial team as they continue to expand their product offerings and services, building a safer, freer internet.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240814518374/en/
Zac Eller (Photo: Business Wire)
The former Sony, Netflix, and Fox executive brings years of successfully scaling subscription-led growth businesses across the technology, media, and digital services sectors through strategic partnerships and new business channels.
In his new role, Eller will lead the group’s global partnerships and business development initiatives for Kape’s privacy products, including its flagship privacy brand, ExpressVPN. Eller will be focused on building new partnerships and B2B channels to drive growth and awareness for Kape’s best-in-category digital apps and services.
At Netflix, Eller contributed to the development of strategic partnerships that enhanced the platform’s global reach and content offerings. During his tenures at Sony and Fox, he spearheaded global partner initiatives, resulting in impactful collaborations that increased brand recognition, drove revenue, and expanded the subscriber base. Most recently, he managed the international digital services business at Travel + Leisure, where he was responsible for launching multi-platform travel products and content.
Ankit Khemka, Kape Technologies and ExpressVPN CMO, says “We are delighted to welcome Zac to the team during this new period of growth and innovation. His extensive experience and demonstrated success in scaling influential digital brands will be invaluable to us as we build a safer, freer digital world.”
“I’m excited to join Kape Technologies and ExpressVPN during this next stage of growth for the company,” says Zac Eller. “ExpressVPN is at the forefront of digital privacy and security innovation, and I look forward to working with the talented team to drive growth and deliver exceptional value to our partners and customers.”
About ExpressVPN
Since 2009, ExpressVPN has empowered millions of users to take control of their internet experience. The company’s award-winning consumer VPN service is backed by its open-source VPN protocol, Lightway, delivering user privacy in just a few clicks. ExpressVPN’s Keys password manager and Aircove router make digital privacy and security easy and accessible for all. ExpressVPN's products have been extensively vetted by third-party experts, including PwC, Cure53, KPMG and others.
ExpressVPN has been part of Kape Technologies since 2021. To learn more about ExpressVPN’s industry-leading privacy and security solutions, visit www.expressvpn.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240814518374/en/
Contacts
Media:
Max Borges Agency for ExpressVPN
expressvpn@maxborgesagency.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 08:00:00 EEST | Press release
The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. The company is one of the leading suppliers of maintenance and modification serv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom